CIMAvax EGF vaccine for stage IIIb/IV non-small cell lung carcinoma.
This case report documents the use of the CIMAvax Epidermal Growth Factor vaccine regimen in a 54 y old female with stage IIIb non-small cell lung carcinoma. Even after 48 mo since diagnosis her ECOG performance remains at zero. Further, this report documents a reaction to the vaccine of grade 3 severity not previously documented.
Monash University Central Medical School, Clayton, VIC, Australia. chengjy88@gmail.com
Jian Y
JY
Cheng
Ratnavelu
R
Kananathan
D019496:Cancer Vaccines / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D007167:Immunotherapy / Q000379:methods*; D008875:Middle Aged; D013902:Radiography, Thoracic; D012720:Severity of Illness Index; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
C550107:CIMAvax EGF; D019496:Cancer Vaccines; D007155:Immunologic Factors